---
title: "Takeda and Iambic announce $1.7bn deal to advance small molecule programmes"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275434293.md"
description: "Takeda has formed a multi-year partnership with Iambic to utilize its AI drug discovery models for small molecule programs, in a deal potentially worth over $1.7 billion. The collaboration will focus on oncology, gastrointestinal, and inflammation projects, granting Takeda access to Iambic's NeuralPLexer model for predicting protein-ligand complexes. Iambic will receive upfront payments, research contributions, technology fees, and royalties on resulting products. Both companies aim to accelerate the development of new therapeutics using advanced AI technology."
datetime: "2026-02-10T09:30:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275434293.md)
  - [en](https://longbridge.com/en/news/275434293.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275434293.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275434293.md) | [繁體中文](https://longbridge.com/zh-HK/news/275434293.md)


# Takeda and Iambic announce $1.7bn deal to advance small molecule programmes

Through this arrangement, Takeda will gain access to NeuralPLexer, Iambic’s model for predicting protein-ligand complexes. Credit: Veroniksha / Shutterstock.com.

Takeda has entered a multi-year partnership to utilise Iambic’s AI drug discovery models for advancing small molecule programmes, in a deal that could exceed $1.7bn.

The Takeda-Iambic AI drug discovery collaboration will initially focus on projects in oncology and gastrointestinal therapeutic area, as well as that of inflammation.

### Go deeper with GlobalData

-   ![ReportsLogo](/wp-content/themes/goodlife-wp-B2B/assets/img/report.png)
    
    Reports
    
    #### NPVM: Bicycle Therapeutics Plc's BT-1718
    
-   ![ReportsLogo](/wp-content/themes/goodlife-wp-B2B/assets/img/report.png)
    
    Reports
    
    #### NPVM: Sanofi's Tusamitamab ravtansine
    

##### Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

#### Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Through this arrangement, Takeda will gain access to Iambic’s model for predicting protein-ligand complexes, NeuralPLexer.

The partnership aims to advance several high-priority small molecule programmes using Iambic’s AI models and automated wet lab capabilities.

Under the deal, Iambic will be eligible for upfront payments, research cost contributions, technology access fees, success-based payments potentially exceeding $1.7bn, plus royalties on net sales of any resulting products.

Iambic co-founder and CEO Tom Miller said: “Our collaboration with Takeda is a powerful opportunity to apply our AI-driven discovery and development platform, and we are excited to partner with their team to quickly advance new and better drug candidates.

GlobalData Strategic Intelligence

# US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Learn more about Strategic Intelligence

“This collaboration further validates our industry-leading technology and highlights both the breadth of our discovery capabilities and the scale at which we can operate.”

Takeda chief scientific officer and research head Chris Arendt said: “We are excited to be able access Iambic’s proprietary computational platform while we work with their team to develop small molecule therapeutics with the potential to address critical unmet patient needs.

“At Takeda, our focus is on accelerating the development of impactful new medicines by leveraging cutting-edge science, including the latest advances in artificial intelligence. Iambic’s small molecule platform aligns with this ambition and offers the potential to de-risk candidate selection, improve the probability of success, and more quickly advance select programmes from early project start to IND \[investigational new drug\].”

Last month, Takeda announced a global collaboration and licence agreement with Halozyme to continue advancing vedolizumab with the latter’s Enhanze drug delivery technology.

### Related Stocks

- [Takeda Pharmaceutical Co. Ltd. (4502.JP)](https://longbridge.com/en/quote/4502.JP.md)
- [Takeda Pharmaceutical Company Limited (TAK.US)](https://longbridge.com/en/quote/TAK.US.md)

## Related News & Research

- [Takeda Pharmaceutical to Cut 400 US Jobs, Invest in Blood Products](https://longbridge.com/en/news/277827484.md)
- [Takeda Pharmaceutical Company Limited Revises Earnings Guidance for the Fiscal Year 2025](https://longbridge.com/en/news/263456709.md)
- [Takeda Pharmaceutical Says NDA for Oveporexton Gets FDA Acceptance](https://longbridge.com/en/news/275444067.md)
- [How FDA Priority Review For Narcolepsy Drug Oveporexton At Takeda Pharmaceutical (TSE:4502) Has Changed Its Investment Story](https://longbridge.com/en/news/276281923.md)
- [FDA nimmt Zulassungsantrag für Oveporexton von Takeda zur Prüfung an](https://longbridge.com/en/news/275421640.md)